Market capitalization | $692.85m |
Enterprise Value | $641.39m |
P/E (TTM) P/E ratio | 37.44 |
EV/FCF (TTM) EV/FCF | 36.03 |
EV/Sales (TTM) EV/Sales | 8.99 |
P/S ratio (TTM) P/S ratio | 9.72 |
P/B ratio (TTM) P/B ratio | 8.30 |
Dividend yield | 0.00% |
Last dividend (FY22) | $0.96 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a iRadimed Corp forecast:
2 Analysts have issued a iRadimed Corp forecast:
Sep '24 |
+/-
%
|
||
Revenue | 71 71 |
13%
13%
|
|
Gross Profit | 55 55 |
15%
15%
|
|
EBITDA | 22 22 |
12%
12%
|
EBIT (Operating Income) EBIT | 21 21 |
11%
11%
|
Net Profit | 19 19 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices and accessories and services. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Head office | United States |
CEO | Roger Susi |
Employees | 148 |
Founded | 1992 |
Website | www.iradimed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.